On the Wednesday, April 15, 2026, episode of The Excerpt podcast: Prices for cutting-edge medical treatments can balloon in the U.S. health care system, leading to higher costs for the employer, ...
Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...
The cancer medication Keytruda is the world’s bestselling drug. But with lower-priced competition set to arrive as soon as 2028, Keytruda’s manufacturer, Merck, is on the brink of losing tens of ...
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
The gap between US drug prices and those abroad is not a market outcome — it is the result of deliberate political and ...
A landmark study by onco-researchers at Tata Memorial Centre has laid bare the brutal arithmetic of modern cancer care. The findings are stark: a standard six-month course of the blockbuster ...
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...
New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results